| Immunology of COVID-19: current state of the science N Vabret, GJ Britton, C Gruber, S Hegde, J Kim, M Kuksin, R Levantovsky, ... Immunity, 2020 | 1711 | 2020 |
| Sinai Immunology Review Project N Vabret, GJ Britton, C Gruber, S Hegde, J Kim, M Kuksin, R Levantovsky, ... Samstein, R., Fernandez, N., Merad, M., Trainees, 2020 | 270* | 2020 |
| Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors A Moreira, C Loquai, C Pföhler, KC Kähler, S Knauss, MV Heppt, ... European Journal of Cancer 106, 12-23, 2019 | 220 | 2019 |
| Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy A Moreira, W Leisgang, G Schuler, L Heinzerling Immunotherapy 9 (2), 115-121, 2017 | 145 | 2017 |
| Vaccines for immunoprevention of cancer. T Enokida, A Moreira, N Bhardwaj The Journal of Clinical Investigation 131 (9), 2021 | 52 | 2021 |
| Current Melanoma Treatments: Where Do We Stand? A Moreira, L Heinzerling, N Bhardwaj, P Friedlander Cancers 13 (2), 221, 2021 | 51 | 2021 |
| Hematological immune related adverse events after treatment with immune checkpoint inhibitors R Kramer, A Zaremba, A Moreira, S Ugurel, DB Johnson, JC Hassel, ... European Journal of Cancer 147, 170-181, 2021 | 49 | 2021 |
| Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients MC Kirchberger, A Moreira, M Erdmann, G Schuler, L Heinzerling Oncotarget 9 (48), 28903, 2018 | 48 | 2018 |
| Senescence markers: Predictive for response to checkpoint inhibitors A Moreira, S Gross, MC Kirchberger, M Erdmann, G Schuler, ... International journal of cancer 144 (5), 1147-1150, 2019 | 42 | 2019 |
| Skin symptoms as diagnostic clue for autoinflammatory diseases A Moreira, B Torres, J Peruzzo, A Mota, K Eyerich, J Ring Anais brasileiros de dermatologia 92 (1), 72-80, 2017 | 29 | 2017 |
| Eosinophil-cationic protein-a novel liquid prognostic biomarker in melanoma A Krückel, A Moreira, W Fröhlich, G Schuler, L Heinzerling BMC cancer 19 (1), 207, 2019 | 27 | 2019 |
| Effective anti‐programmed death‐1 therapy in a SUFU‐mutated patient with Gorlin–Goltz syndrome A Moreira, MC Kirchberger, F Toussaint, M Erdmann, G Schuler, ... British Journal of Dermatology 179 (3), 747-749, 2018 | 27 | 2018 |
| Checkpoint inhibitor-induced eosinophilic fasciitis following high eosinophilia associated with complete response F Toussaint, M Hammon, M Erdmann, A Moreira, MC Kirchberger, ... Rheumatology, 2019 | 16 | 2019 |
| Blood eosinophilia is an on-treatment biomarker in patients with solid tumors undergoing dendritic cell vaccination with autologous tumor-RNA A Moreira, M Erdmann, U Uslu, V Vass, G Schuler, B Schuler-Thurner Pharmaceutics 12 (3), 210, 2020 | 6 | 2020 |
| Dendritic cell vaccination in metastatic uveal melanoma as compassionate treatment: Immunological and clinical responses. A Moreira, S Gross, U Uslu, J Doerrie, M Kummer, S Schliep, F Sponagl, ... Journal of Clinical Oncology 37 (15_suppl), e21024-e21024, 2019 | 5 | 2019 |
| MAPK blockade, toxicities, pathogenesis and management. A Moreira, C Lebbé, L Heinzerling Current Opinion in Oncology, 2020 | 3 | 2020 |
| Current Melanoma Treatments: Where Do We Stand? Cancers 2021, 13, 221 A Moreira, L Heinzerling, N Bhardwaj, P Friedlander s Note: MDPI stays neu-tral with regard to jurisdictional clai-ms in …, 2021 | 1 | 2021 |
| Eosinophilic count as a biomarker for prognosis of melanoma patients A Moreira, L Heinzerling JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT 15, 14-15, 2017 | 1 | 2017 |
| DOENÇAS BOLHOSAS AUTOIMUNES ÁAM dos Santos Soares, OCSF Rodrigues, AJV Mota Journal of the Portuguese Society of Dermatology and Venereology 71 (3), 325-335, 2013 | 1 | 2013 |
| ECP as prognostic Marker for Melanoma A Moreira, A Krueckel, G Schuler, J Utikal, L Heinzerling JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT 17, 27-28, 2019 | | 2019 |
